Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,317,607 papers from all fields of science
Search
Sign In
Create Free Account
LY 333328
Known as:
LY-333328
, LY333328
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
oritavancin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A new assay to determine Oritavancin concentrations
C. Vidaillac
,
J. Aeschlimann
,
M. Rybak
Journal of antibiotics (Tokyo. )
2010
Corpus ID: 19069551
Oritavancin (The Medicines Company, St Laurent, Quebec, CA, USA) is an investigational parenteral lipoglycopeptide antibiotic…
Expand
2005
2005
Mixed-Lipid Storage Disorder Induced in Macrophages and Fibroblasts by Oritavancin (LY333328), a New Glycopeptide Antibiotic with Exceptional Cellular Accumulation
F. Van Bambeke
,
Jennifer Saffran
,
M. Mingeot-Leclercq
,
P. Tulkens
Antimicrobial Agents and Chemotherapy
2005
Corpus ID: 847585
ABSTRACT Oritavancin, a semisynthetic derivative of vancomycin endowed with a cationic amphiphilic character, accumulates to…
Expand
2003
2003
Pharmacodynamics of Oritavancin ( LY 333328 ) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection
C. Boylan
,
K. Campanale
,
P. Iversen
,
D. Phillips
,
M. Zeckel
,
T. Parr
2003
Corpus ID: 35553907
The pharmacokinetics and pharmacodynamics of oritavancin (LY333328), a glycopeptide antibiotic with concentration-dependent…
Expand
2001
2001
The antibiotic food-chain gang.
P. Courvalin
Emerging Infectious Diseases
2001
Corpus ID: 29441628
489 Vol. 7, No. 3, May–June 2001 Emerging Infectious Diseases of serious gram-positive infections in humans (with no animal use…
Expand
1999
1999
Evaluation of the macrocyclic antibiotic LY333328 as a chiral selector when used as a mobile phase additive in narrow bore HPLC.
V. S. Sharp
,
D. S. Risley
Chirality
1999
Corpus ID: 12453825
The macrocyclic antibiotic LY333328 has been evaluated as a chiral selector for the enantioseparation of nine dansylated amino…
Expand
1999
1999
Vancomycin-resistant Enterococcus: Infectious endocarditis treatment
M. Rybak
,
Elizabeth A. Coyle
Current Infectious Disease Reports
1999
Corpus ID: 23517246
Vancomycin-resistant Enterococcus species represent serious gram-positive pathogens for which there is currently no recommended…
Expand
1998
1998
ANTIMICROBIAL SUSCEPTIBILITY STUDIES In Vitro Activity of LY333328 Against Vancomycin-Resistant Enterococci, Methicillin-Resistant Staphylococcus aureus, and Penicillin-Resistant Streptococcus…
Robin Patel
,
M. Rouse
,
K. Piper
,
F. Cockerill
,
J. Steckelberg
1998
Corpus ID: 90646460
We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying…
Expand
1997
1997
In-vitro susceptibility to LY333328 of vancomycin-resistant enterococci isolated from humans and animals.
F. V. van Tiel
,
T. van den Bogaard
Journal of Antimicrobial Chemotherapy
1997
Corpus ID: 33133298
1997
1997
The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
M. Kirk
,
R. Hill
,
M. Casewell
,
D. Beighton
Advances in Experimental Medicine and Biology
1997
Corpus ID: 43638545
Vancomycin has been the mainstay of treament for infections caused by multiply-resistant enterococci and staphylococci. The…
Expand
1995
1995
Monthly Update Anti-infectives: LY333328, a new glycopeptide active against vancomycin-resistant enterococci
Marriott
1995
Corpus ID: 72991890
LY333328 is a novel glycopeptide from Lilly Research Laboratories which is claimed to have activity both in vitro and in vivo…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE